Once-weekly exenatide as a treatment for Type 2 diabetes

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States A, GA: US Department of Health and Human Services. 2014. Available from: www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html [Accessed 20 February 2015]
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes care 2015;38(suppl 1):S1-94
   PubMed Web of Science ®Google Scholar
• Byetta [prescribing information]. Amylin Pharmaceuticals Inc.; December 2014. Available from: www.byettahcp.com [Last accessed February 20]
   Google Scholar
• Bydureon [prescribing information]. AstraZeneca; January 2015. Available from: www.bydureonhcp.com [Last accessed February 20]
   Google Scholar
• Drucker DJ NM. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33(6):1255-61
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2(6):464-73
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012;35(4):683-9
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375(9733):2234-43
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
   PubMed Web of Science ®Google Scholar
• Macconell L, Pencek R, Li Y, et al. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes 2013;6:31-41
   PubMedGoogle Scholar
• Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9
   PubMed Web of Science ®Google Scholar
• Wysham CH, MacConell LA, Maggs DG, et al. Five-Year Efficacy and Safety Data of Exenatide Once Weekly: Long-term Results From the DURATION-1 Randomized Clinical Trial. Mayo Clin Proc 2015;90(3):356-65
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376(9739):431-9
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96(5):1301-10
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381(9861):117-24
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35(2):252-8
   PubMed Web of Science ®Google Scholar
• Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 2013;36(5):1368-76
   PubMed Web of Science ®Google Scholar
• Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 2012;34(9):1892-908; e1891
   PubMed Web of Science ®Google Scholar
• Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4(1):53-61
   PubMed Web of Science ®Google Scholar
• Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol 2015;14(1):12
   PubMedGoogle Scholar
• Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 2014;31(11):1119-33
   PubMed Web of Science ®Google Scholar
• Saunders W NH, Kalsekar I. Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus. Diabetologia 2014;57(Suppl 1):S335-6
   Google Scholar
• Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14(3):357-66
   PubMedGoogle Scholar
• Fonseca T, Clegg J, Caputo G, et al. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index >/=30 kg/m(2) in Spain. J Med Econ 2013;16(7):926-38
   PubMedGoogle Scholar
• Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag 2012;8:255-64
   PubMedGoogle Scholar
• Guillermin AL, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ 2012;15(4):654-63
   PubMedGoogle Scholar
• Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ 2012;15(Suppl 2):6-13
   PubMedGoogle Scholar
• Bellows B, Hunter E, McAdam-Marx C. Exenatide: review of its role as adjunctive therapy in patients with type 2 Diabetes. Clin Med Rev Vascular Health 2011;3
   Google Scholar
• Quintiles Brochure. Available from: www.quintiles.com/∼/media/library/brochures/real%20world%20late%20phase%20research%20expertise%20in%20diabetes%20deliver%20tangible%20value%20with%20the%20right%20answer.pdf
   Google Scholar
• Bootman J, Townsend R, McGhan W. Principles of Pharmacoeconomics. 3rd edition. W. Harvey Whitney Books Co; Cincinnati, OH: 2005
   Google Scholar
• National Institute for Health and Clinical Experience. Guide to Methods of Technical Appraisal. National Institute for Clinical Excellence; London, U.K: 2004
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 2015;38(1):140-9
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2013;19(2):327-36
   Google Scholar
• Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag 2012;8:621-9
   PubMedGoogle Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384(9951):1349-57
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009;374(9683):39-47
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes care 2009;32(1):84-90
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The lancet. Diabetes & endocrinology 2014;2(4):289-97
   PubMed Web of Science ®Google Scholar
• Company B-MS. Bydureon (Exenatide Once Weekly) Prescribing Information. Wilmington, DE 2013
   Google Scholar
• Eli Lilly & Co. Trulicity (Dulaglutide) Prescribing Information. Indianapolis, IN 2014
   Google Scholar
• GlaxoSmithKline. Tanzeum (Albiglutide) Prescribing Information. Research Triangle Park, NC 2014
   Google Scholar
• NovoNordisk. Victoza (Liraglutide) Prescribing Information. Plainsburo, NJ 2013
   Google Scholar
• Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes care 2009;32(10):1880-6
   PubMed Web of Science ®Google Scholar
• Red Book Online. Truven Analytics. Available from: www.redbook.com/redbook/ [Last accessed 27 February 27, 2015]
   Google Scholar
• Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15(6):485-502
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. ClinicalTrials.gov. 2015; Available from: www.clinicaltrials.gov/ct2/home. [Accessed 27 February]
   Google Scholar
• Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes research and clinical practice 2013;100(2):e55-58
   PubMed Web of Science ®Google Scholar
• Raman VS, Mason KJ, Rodriguez LM, et al.The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33(6):1294-6
   PubMed Web of Science ®Google Scholar
• Lee JS, Sheer JL, Lopez N, Rosenbaum S. Coverage of obesity treatment: a state-by-state analysis of Medicaid and state insurance laws. Public health reports 2010;125(4):596-604
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Fact Sheet: Preventive Services Covered by Private Health Plans under the Affordable Care Act. 2014. Available from: http://files.kff.org/attachment/preventive-services-covered-by-private-health-plans-under-the-affordable-care-act-fact-sheet. [Accessed 27 February 2015]
   Google Scholar